Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients
Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients is a registry-stage clinical asset sponsored by H. Lee Moffitt Cancer Center and Research Institute in Covid19, SARS-CoV2 Infection. SEO and diligence focus: mRNA-1273, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Covid19
Modality: RNA therapy
Target: mRNA-1273
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: mRNA-1273
View original source fields
Condition raw: Covid19, SARS-CoV2 Infection
Condition normalized: Covid19, SARS-CoV2 Infection
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: mRNA-1273
Target normalized: mRNA-1273